Source: Annual Congress 2005 - Pulmonary fibrosis and pleural disease



Rating:

Share or cite this content

Citations should be made in the following way:
N. A. Wilson, J. D. Moffatt, W. C. Yu, G. J. Laurent, R. C. Chambers, Y. C. G. Lee (London, United Kingdom; Hong Kong, Hong Kong). Thrombin and its major receptor - proteinase-activated receptor (PAR)-1 - in pleural disease. Eur Respir J 2005; 26: Suppl. 49, 3567

Member's Comments

No comment yet.

Related content which might interest you: Protease-activated receptor 2 (PAR2) stimulation potentiates citric acid induced cough by sensitising the vanilloid receptor-1 (TRPV1) Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003 A possible role for toll-like receptor (TLR) 5 in fibrotic pulmonary sarcoidosis Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008 Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1? synthesis by human neutrophils Source: Eur Respir J 2011; 37: 406 Year: 2011 Pneumolysin mediates neutrophil:platelet aggregation via a P-selectin- and protease-activated receptor-1 (PAR-1)-dependent mechanism Source: International Congress 2017 – How can microbiology and translational research help physicians? Year: 2017 Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling Source: Eur Respir Rev 2008; 17: 130-137 Year: 2008 Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005 Toll-like receptor 9 agonists prolong human eosinophil survival Source: Annual Congress 2007 - Mechanisms of inflammation in asthma and rhinitis - from cell cultures to patients Year: 2007 Enhanced platelet activating factor receptor (PAFR) expression in smoker airways Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections Year: 2011 Protease activated receptor-1 (PAR-1) stimulation leads to αvβ6 integrin mediated TGFβ activation via rho kinase Source: Eur Respir J 2005; 26: Suppl. 49, 238s Year: 2005 Dual endothelin receptor blockade: advances in pulmonary disease Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience Year: 2008 Protease-activated receptor-2 triggers epithelial to mesenchymal transition: Potential relevance in pulmonary fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Extracellular ATP is a danger signal activating P2X7 Receptor in a LPS mediated inflammation (ARDS/ALI) Source: International Congress 2019 – Identification of new targets and therapeutic strategies for lung disease Year: 2019 Role of leukotriene receptor antagonist on TGF-β1 and Smad signalling in bleomycin induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Serotonin (5-hydroxytryptamine) modulates cytokine and chemokine production in lipopolysaccharide-primed human monocytes via stimulation of different 5-HT receptor subtypes Source: Annual Congress 2005 - Inflammation and remodelling in allergy and asthma Year: 2005 Protease-activated receptor 1 activation exaggerates allergic airway inflammation in mice Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008 The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 Elevated CCL2 responses in COPD and attenuation by selective chemokine receptor antagonists Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015